当前位置： SCI文献检索 > JOURNAL OF THROMBOSIS AND THROMBOLYSIS期刊下所有文献 > Bleeding risk factors associated with argatroban therapy in the critically ill.

Bleeding risk factors associated with argatroban therapy in the critically ill.

Abstract：

:Argatroban is a parenteral direct thrombin inhibitor labeled for anticoagulation in patients with confirmed or suspected heparin-induced thrombocytopenia in the United States. Currently there are no studies evaluating bleeding risk factors in Intensive Care Unit patients.To determine bleeding risk factors associated with argatroban therapy in the critically ill. Critically ill patients admitted between July 2007-June 2008 who received argatroban were included in this retrospective cohort study. The primary endpoint was the incidence of bleeding complications associated with argatroban. Major bleeding was defined as a hemoglobin reduction ≥2 g/dL plus a transfusion of ≥2 units of blood in a 24 h period, or a retroperitoneal, intracranial, prosthetic joint, or other life-threatening bleed. Minor bleeding was any overt bleeding not fitting the major bleeding definition. Secondary outcomes included identifying risk factors for bleeding. Seventy-three patients were included with 16 (21.9%) total bleeding complications, 7 (9.6%) major and 9 (12.3%) minor bleeds. Four risk factors for bleeding were identified by univariate analysis: major surgery prior to or during argatroban therapy (OR = 8.4, 95% CI: 2.3-30.1, p = 0.001), dosing weight >90 kg (OR = 4.8, 95% CI: 1.4-15.8, p = 0.01), total bilirubin >3 mg/dL (OR = 8.1, 95% CI: 2.1-31.1, p = 0.002), and baseline platelets ≤70 K/μL (OR = 4.2, 95 % CI: 1.1-16.3, p = 0.039).Risks and benefits of argatroban should be weighed in patients with major surgery prior to or during argatroban, dosing weight ≥90 kg, total bilirubin ≥3 mg/dL, and baseline platelets ≤70 K/μL.

journal_name

J Thromb Thrombolysis

journal_title

Journal of thrombosis and thrombolysis

authors

Doepker B,Mount KL,Ryder LJ,Gerlach AT,Murphy CV,Philips GS

doi

10.1007/s11239-012-0758-y

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

491-8

issue

4

eissn

0929-5305

issn

1573-742X

journal_volume

34

pub_type

临床试验,杂志文章

相关文献

JOURNAL OF THROMBOSIS AND THROMBOLYSIS文献大全
  • Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.

    abstract：:Apixaban is effective and safe for preventing stroke, and its usage has increased exponentially in recent years. However, data concerning the therapeutic range of apixaban is limited. This study determined the trough and peak levels of apixaban-specific anti-factor Xa activity (AFXaA) in acute ischemic stroke patients...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-017-1590-1

    authors： Shin H,Cho MC,Kim RB,Kim CH,Choi NC,Kim SK,Koh EH

    更新日期：2018-02-01 00:00:00

  • Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

    abstract：:A cardiocerebral ischemic attack (CCI) or a concurrent acute ischemic stroke (AIS) and myocardial infarction (AMI) is a severe event with no clear recommendations for ideal management because of the rarity of the scenario. The narrow time window for treatment and complexity of the treatment decision puts immense press...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-017-1484-2

    authors： Yeo LLL,Andersson T,Yee KW,Tan BYQ,Paliwal P,Gopinathan A,Nadarajah M,Ting E,Teoh HL,Cherian R,Lundström E,Tay ELW,Sharma VK

    更新日期：2017-07-01 00:00:00

  • Embolic events caused by aortic thrombi: an underestimated entity?

    abstract：:Stroke and other thromboembolic events are mainly caused by emboli from heart, aorta and other arteries. In this paper we describe a group of 5 middle-aged patients suffering from emboli caused by large thrombi in the aorta. Since the development of giant thrombi under high flow conditions in the aorta is a pathophysi...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-012-0775-x

    authors： Stoevesandt D,Klempt C,Scheubel R,Herr W,Hettwer S,Werdan K,Silber RE,Kraya T,Thews O,Schlitt A

    更新日期：2013-02-01 00:00:00

  • PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count.

    abstract：:Peripherally inserted central catheters (PICCs) for central venous access are frequently used in patients with hematological malignancies. Their use may be complicated by upper extremity deep venous thrombosis (UEDVT). Additionally, hematological patients are frequently thrombocytopenic and the optimal management of U...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02040-8

    authors： Scamuffa MC,Morano SG,Serrao A,Bruzzese A,Stocchi F,Santoro C,Vozella F,Latagliata R,Chistolini A

    更新日期：2020-04-01 00:00:00

  • Management of periprocedural anticoagulant therapy: a novel individualized approach-a transeusophageal echocardiographic study.

    abstract：:Patients with non-valvular atrial fibrillation who are under chronic oral anticoagulant therapy (OAC) treatment frequently require interruption of OAC treatment. By examining the presence of left atrial/left atrial appendage (LA/LAA) thrombus or dense spontaneous echo contrast (SEC) with transesophageal echocardiograp...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02104-9

    authors： Durmaz E,Karadag B,İkitimur B,Ebren C,Tokdil H,Koca D,Ozmen E,Polat F,Ohtaroglu Tokdil K,Raimoglu U,Mutlu D,Atici A,Ongen Z

    更新日期：2020-08-01 00:00:00

  • 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.

    abstract：BACKGROUND AND OBJECTIVE:The 4G/5G plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism has been associated with basal PAI-1 levels, with ischemic heart disease, and with adverse prognosis in critically ill patients. We hypothesized it might also influence the acute-phase levels of PAI-1 following coronary b...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/B:THRO.0000024052.79415.62

    authors： Burzotta F,Iacoviello L,Di Castelnuovo A,Zamparelli R,D'Orazio A,Amore C,Schiavello R,Donati MB,Maseri A,Possati G,Andreotti F

    更新日期：2003-12-01 00:00:00

  • Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).

    abstract：:While antithrombotic therapy of acute myocardial infarction is clearly beneficial, substantial controversy exists regarding the optimal regimen. In particular, while aspirin alone has proven highly effective in reducing rates of reinfarction, stroke, and death following acute coronary occlusion, heparin has not clearl...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF01062568

    authors： Ridker PM,O'Donnell CJ,Hennekens CH

    更新日期：1995-01-01 00:00:00

  • Repeated early thrombolysis in cervical spinal cord ischemia.

    abstract：:Specific therapy of acute spinal ischemia is not established. We report the first case of an MRI-verified cervical spinal ischemia treated by thrombolysis and review the literature. A 72-year old woman with right-sided motor hemiparesis and trunk ataxia was treated by intravenous thrombolysis with full recovery. Three...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-015-1332-1

    authors： Etgen T,Höcherl C

    更新日期：2016-07-01 00:00:00

  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study.

    abstract：:The relation of device related thrombosis (DRT) and major bleeding after left atrial appendage closure (LAAC) to laboratory thrombosis and hemostasis markers has not been studied. We performed a prospective case control study to identify clinical characteristics and laboratory markers in patients who developed DRT and...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02205-5

    authors： Sherwood M,Bliden KP,Ilkhanoff L,Venkataraman G,Strickberger A,Yazdani S,McSwain R,Rashid H,Navarese EP,Plummer T,Batchelor W,Chaudhary R,Tantry US,Gurbel PA

    更新日期：2020-10-01 00:00:00

  • Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.

    abstract：:A 64-year-old man first developed ligneous conjunctivitis at the age of 58 years after right pulmonary resection because of suspected cancer; otherwise, he had been healthy. Since then, he began to suffer from various forms of chronic pseudomembranous mucositis. Laboratory tests demonstrated that he had 7.8 % of plasm...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-016-1375-y

    authors： Osaki T,Souri M,Song YS,Izumi N,Law R,Ichinose A

    更新日期：2016-08-01 00:00:00

  • Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge.

    abstract：:Many hospitals have implemented warfarin dosing nomograms to improve patient safety. To our knowledge, no study has assessed the impact inpatient warfarin initiation has in both medical and surgical patients, on safety outcomes post discharge. To evaluate the impact of a suggested institutional nomogram for the initia...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-016-1462-0

    authors： Chamoun N,Macías CG,Donovan JL,Klugman R,Gore J,Salameh P,Tran MT

    更新日期：2017-05-01 00:00:00

  • Aspirin dosing in cardiovascular disease prevention and management: an update.

    abstract：:Aspirin has been in use for prevention and management of cardiovascular diseases for several decades. Clinical and epidemiological literature suggests that while net benefits of aspirin in primary prevention of CVDs are less clear, the benefits of aspirin in acute scenarios and secondary prevention settings are well e...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-015-1267-6

    authors： Ganjehei L,Becker RC

    更新日期：2015-11-01 00:00:00

  • Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation.

    abstract：:Whitmania pigra Whitman (W. pigra) has been widely employed in decoction for the treatment of blood stasis syndrome for many years in China. The aim of the present study was to explore the anti-venous thrombosis (VT) mechanism of the aqueous extract of W. pigra (AEW) in rats. Rats were orally administered with AEW. A ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02337-8

    authors： Li P,Lin B,Tang P,Ye Y,Wu Z,Gui S,Zhan Y,Yang W,Lin B

    更新日期：2020-11-17 00:00:00

  • Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable

    abstract：:Amlodipine, commonly used for relief of ischemic symptoms in coronary artery disease (CAD), may affect clopidogrel-induced antiplatelet effects. It remains unknown if ranolazine, an antianginal drug that constitutes a pharmacologic alternative to calcium channel blockade, interferes with clopidogrel-induced antiplatel...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11239-015-1203-9

    authors： Pelliccia F,Greco C,Gaudio C,Rosano G,Vitale C,Marazzi G,Rollini F,Angiolillo DJ

    更新日期：2015-10-01 00:00:00

  • Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

    abstract：:Warfarin is among the ten drugs most commonly involved in adverse drug reactions, has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions. To analyze the profile of pharmacoepidemiological drug prescriptions for warfarin in patients ad...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-013-1030-9

    authors： Guidoni CM,Obreli-Neto PR,Pereira LR

    更新日期：2014-05-01 00:00:00

  • Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds.

    abstract：:The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring, however emergency measurements are gaining importance. Current assays feature good performance at intermediate and high dabigatran concentrations but show limited accuracy at low concentrations. This area requires more attention as ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-019-01981-z

    authors： Härtig F,Poli S,Ebner M,Birschmann I,Kuhn J,Ziemann U,Häring HU,Lehmann R,Peter A,Hörber S

    更新日期：2020-04-01 00:00:00

  • Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.

    abstract：:Kuperman et al. found that patients with anemia had a higher risk of major bleeding (RR 2.84; 95% CI 2.52-3.39) in RIETE database. Anemia appeared to be an independent predictive factor for major bleeding [hazard ratio (HR) 1.95; 95% CI 1.72-2.20] in this registry. Unfortunately, selection bias due to enrolled patient...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 信件,多中心研究

    doi：10.1007/s11239-018-1668-4

    authors： Gaboreau Y,Zenatti N,Vermorel C,Imbert P,Bosson JL,Pernod G

    更新日期：2018-07-01 00:00:00

  • Standard or extended-duration prophylaxis in medical patients? A review of the evidence.

    abstract：:Acutely ill medical patients are at significant risk of venous thromboembolism (VTE). Thromboprophylaxis can substantially reduce the incidence of VTE, but to be optimally effective must consist of the correct choice of agent, at an appropriate dose, and for sufficient duration. Increasing evidence suggests that VTE r...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-011-0594-5

    authors： Stark JE,Smith WJ

    更新日期：2011-10-01 00:00:00

  • Direct oral anticoagulants in hypercoagulable states.

    abstract：:Direct oral anticoagulants have been shown safe and effective in the treatment of pulmonary emboli and deep vein thrombi. Their role in the treatment of patients with hypercoagulability is uncertain. We designed a retrospective exploratory analysis of all patients with definite heparin induced thrombocytopenia (HIT) a...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-016-1420-x

    authors： Kunk PR,Brown J,McShane M,Palkimas S,Gail Macik B

    更新日期：2017-01-01 00:00:00

  • Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study.

    abstract：:The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thro...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02169-6

    authors： Limperger V,Kenet G,Kiesau B,Köther M,Schmeiser M,Langer F,Juhl D,Shneyder M,Franke A,Klostermeier UK,Mesters R,Rühle F,Stoll M,Steppat D,Kowalski D,Rocke A,Kuta P,Bajorat T,Torge A,Neuner B,Junker R,Nowak-Göttl

    更新日期：2020-06-27 00:00:00

  • The effect of cessation of 2nd generation P2Y12 inhibitor therapy on platelet reactivity in patients 1 year after acute myocardial infarction.

    abstract：:To assess the effect of cessation of dual antiplatelet therapy (DAPT) regimens containing 2nd generation P2Y12 inhibitors on platelet reactivity, in patients who completed 12 months of DAPT following an acute myocardial infarction. Clinical data has shown an increased cardiovascular risk in the 90 days following cessa...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-018-1701-7

    authors： Witberg G,Bathish J,Bental T,Leshem-Lev D,Assali A,Kornowski R,Lev E

    更新日期：2018-10-01 00:00:00

  • The impact of proton therapy on cardiotoxicity following radiation treatment.

    abstract：:Cardiac disease following radiation therapy represents a major consideration in the treatment of a variety of malignancies. Damage to the heart can manifest in a variety of pathologies including ischemic cardiac disease, cardiomyopathy, valvular dysfunction, arrhythmias, and pericarditis. This damage has been shown to...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-020-02303-4

    authors： Frankart AJ,Nagarajan R,Pater L

    更新日期：2020-10-08 00:00:00

  • The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.

    abstract：OBJECTIVES:The aim of our study was to determine the relation between exercise stress test and aspirin resistance in patients with stable coronary artery disease. BACKGROUND:Clinically aspirin resistance is defined as having thrombotic and embolic cardiovascular events despite regular aspirin therapy. METHODS:We stud...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-005-2318-1

    authors： Pamukcu B,Oflaz H,Acar RD,Umman S,Koylan N,Umman B,Nisanci Y

    更新日期：2005-08-01 00:00:00

  • The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

    abstract：:According to our personal experience and to the study of the literature, 11 cases of venous thrombosis have been described as sporadic reports in patients with severe (homozygous) factor XII (FXII) deficiencies. In every cases but 4, associated risk factors were found to be present (pregnancy, post-partum period, surg...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1023/B:THRO.0000037670.42776.cd

    authors： Girolami A,Randi ML,Gavasso S,Lombardi AM,Spiezia F

    更新日期：2004-04-01 00:00:00

  • Lipid rich plaque, female gender and proximal coronary stent edge dissections.

    abstract：:We hypothesized that women are more prone to develop coronary dissections during PCI due to potential balloon-oversizing or gender specific plaque and vascular characteristics. To date, a gender related difference in edge dissection has not been systematically studied. The Massachusetts General Hospital Optical Cohere...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11239-013-0882-3

    authors： Zeglin-Sawczuk M,Jang IK,Kato K,Yonetsu T,Kim S,Choi SY,Kratlian C,Lee H,Dauerman HL

    更新日期：2013-11-01 00:00:00

  • Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin at Patient's Home.

    abstract：:We have applied the low molecular weight heparin dalteparin as once-daily subcutaneous injections to the treatment of deep vein thrombosis (DVT) on an outpatient basis since 1994. Until today, 377 consecutive patients with DVT below the inguinal ligament have been treated at home with dalteparin. The patients administ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/A:1008866025015

    authors： Stockelberg D,Hansson E,Jonson T

    更新日期：1998-09-01 00:00:00

  • Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study.

    abstract：:Bleeding refers to the most important complication during anticoagulation therapy in patients with pulmonary embolism (PE). However, the incidence and risk factors of bleeding in Chinese population with anticoagulant therapy remains unknown. Although diabetes mellitus (DM) has been demonstrated to increase the risk of...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-017-1473-5

    authors： Zhang Z,Zhai Z,Yang Y,Wan J,Xie W,Zhu J,Shen YH,Wang C

    更新日期：2017-05-01 00:00:00

  • Osteoprotegerin is not associated with angiographic coronary calcification.

    abstract：UNLABELLED:Coronary artery calcification may play a significant role in the pathophysiology of plaque progression and healing. We hypothesized that osteoprotegerin, an inhibitor of osteoclastogenesis, may participate in the calcification of coronary plaques or the response to injury after coronary stenting. A prospecti...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-006-9026-3

    authors： Gogo PB Jr,Schneider DJ,Terrien EF,Sobel BE,Dauerman HL

    更新日期：2006-12-01 00:00:00

  • Coronary artery fistulae.

    abstract：:Coronary artery fistulae (CAF) are rare congenital or acquired in which a connection forms between one of the coronary arteries and a heart chamber or with other vessels. This paper describes three cases of CAF along with their initial presentation, imaging findings and management. The first case is a rare form of CAF...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-019-01897-8

    authors： Ali M,Kassem KM,Osei K,Effat M

    更新日期：2019-08-01 00:00:00

  • A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.

    abstract：:The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known. This was a randomised, open-label, crossover PD/PK study of 40 Hispanic...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11239-014-1135-9

    authors： Price MJ,Clavijo L,Angiolillo DJ,Carlson G,Caplan R,Teng R,Maya J

    更新日期：2015-01-01 00:00:00